- Q4 Revenue Growth: Revenue reached $145M, a 5% YoY increase, with $107M in free cash flow, reflecting strong financial performance.
- Full-Year Financials: $645M in revenue (13% YoY growth) and 55% adjusted EBITDA margin, highlighting operational efficiency.
- AI Traction: AI search and scribe active users tripled in 9 months post-Pathway acquisition, with 140 hospital clients and 250k+ HIPAA-compliant physicians.
- Market Opportunity: AI search expects a multibillion-dollar TAM, with 48% of U.S. doctors in hospitals using workflow/scheduling tools.
- Future Guidance: $664-676M FY27 revenue and $323-335M adjusted EBITDA, alongside a $493M remaining share repurchase program.
AI Adoption Accelerates
Doximity’s “AI investment year” shows traction: 30% YoY growth in workflow usage and a tripling of AI search and scribe active users over the past nine months since Pathway acquisition. With 140 hospital enterprise clients and over 250,000 doctors authorized to use its tools, the company is poised to capture a multibillion‑dollar TAM for AI search alone, driving both engagement and incremental revenue.
Market Dynamics Shift
Customer buying behavior is evolving toward shorter‑term commitments amid market uncertainty, reducing revenue visibility. Regulatory scrutiny in the HCP marketing segment remains a concern, yet the company believes its AI product will offset these pressures later this fiscal year. Pharmaceutical clients are tightening budgets, favoring flexible contracts, but still prioritize high‑ROI solutions like Doximity’s AI Search.
Pricing Strategy & Margins
While AI compute costs will pressure gross margins, Doximity is not pursuing price cuts. Instead, it is leveraging higher prices for shorter‑term contracts and emphasizing the value of its physician‑first offerings. The firm’s focus on ROI‑driven spend keeps it competitive without eroding profitability.
Capital Allocation & Share Repurchase
The company maintains a $493 million share repurchase program and generated $317 million in free cash flow for the full fiscal year, yielding a free‑cash‑flow yield of 9.58%. With a negative net debt/EBITDA of –0.85, Doximity has ample liquidity to fund growth initiatives while returning capital to shareholders.